Lexicon Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
lower operating expenses during its fourth-quarter and full-year 2025 earnings call held March 5, 2026. Management emphasized near-term regulatory and clinical milestones for sotagliflozin in type 1 diabetes and hypertrophic cardiomyopathy (HCM), continued partnering efforts for the chronic pain candidate pilavapadin, and milestone-driven progress for the obesity program LX9851 under its license with Novo Nordisk. Pipeline priorities and 2026 milestones Chief Executive Officer Dr. Mike Exton said the company is advancing three “strong novel late-stage programs” spanning cardiometabolic disease and chronic pain: sotagliflozin in HCM and type 1 diabetes (T1D), pilavapadin for diabetic peripheral neuropathic pain (DPNP), and LX9851 in obesity (being developed by Novo Nordisk). ? IonQ in Rebound Mode: Buy the Thesis, Respect the Risk Exton highlighted several 2026 goals: SONATA-HCM Phase III trial: Enrollment is “enrolling well,” and the company expects to complete enrollment by
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVOPR Newswire
- Harbor International Compounders Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Could popular weight loss drugs become the new treatment for addiction? Evidence is starting to mount [CNN]CNN
- Could popular weight loss drugs become the new treatment for addiction? Evidence is starting to mount [CNN]CNN
- Novo Nordisk Gets FDA Warning Over Ozempic Ad [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- 2/23/26 - Form 6-K
- NVO's page on the SEC website